{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-010569","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.895496+00:00","generated_at":"2026-06-04T23:32:28.327213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Champions Oncology Q3 revenue down 6% to $12.0M; operating loss widens to $2.6M","bullets":["Q3 FY2024 revenue $12.0M, down from $12.8M YoY; gross margin fell to 34.7% from 39.7%.","Operating loss of $2.6M vs $2.5M a year ago; adjusted EBITDA loss of $1.7M.","Nine-month revenue $36.2M, down 11.4%; operating loss of $7.1M vs $2.7M loss YoY.","Cash and equivalents $4.5M at quarter end; no debt outstanding.","Company seeking capital for Corellia AI subsidiary; two lead targets progress toward licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-010569","json":"https://secwatch.observer/filing/0001628280-24-010569.json","markdown":"https://secwatch.observer/filing/0001628280-24-010569.md","text":"https://secwatch.observer/filing/0001628280-24-010569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/0001628280-24-010569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/csbr-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:32:28.327213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb425b0f4b803d1b070cc01a7f44ce8b84044dcf","claim":"CHAMPIONS ONCOLOGY, INC. reported third quarter ended January 31, 2024 results: revenue $12.0 million.","evidence_excerpt":"Champions Oncology Reports Quarterly Revenue of $12.0 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/0001628280-24-010569-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended January 31, 2024"},{"label":"Revenue","value":"$12.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ffd0d1ad9497b7b4094722e5406dbdf3f1aa3ffd","claim":"CHAMPIONS ONCOLOGY, INC. reported first nine months of fiscal 2024 results: revenue $36.2 million.","evidence_excerpt":"For the first nine months of fiscal 2024, revenue decreased 11.4% to $36.2 million compared to $40.8 million for the first nine months of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/0001628280-24-010569-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first nine months of fiscal 2024"},{"label":"Revenue","value":"$36.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}